Obesity Drug Outcome Measures: Results of a Multi-Stakeholder Critical Dialogue

被引：7

作者：

Kahan S. ^{[1
]}

Ferguson C. ^{[2
]}

David S. ^{[2
]}

Divine L. ^{[2
]}

机构：

[1] The George Washington University, WA, DC, 20036, 1828 L Street, NW

[2] The George Washington University, WA, DC, 20006, 2021 K Street, NW

来源：

Current Obesity Reports | 2013年 / 2卷 / 2期

关键词：

Drugs; FDA; Feeling; Food and drug administration; Function; Obesity; Outcome measures; Pharmaceuticals; Regulation; Regulatory; Survival; Weight; Weight-loss;

D O I：

10.1007/s13679-013-0052-0

中图分类号：

学科分类号：

摘要：

There has been great interest in what role drugs should play in the treatment of obesity. Given the complex and multifactorial nature of obesity, drugs represent a valuable adjunct to traditional obesity treatments. However, obesity drugs present specific regulatory challenges, due to the sheer number of individuals affected, the heterogeneity of how obesity affects individuals differently, and the potential for drugs to be misused, especially by those seeking or profiting from cosmetic weight loss. There is a need to refine the characterization of the individuals most at risk from obesity to better assess the balance of benefits versus risks and determine appropriate candidates for drug therapy. As obesity affects feeling, functioning, and survival, outcome measures that reflect improvement in these domains should be explicitly incorporated into regulatory guidance. Regulators could benefit from mechanisms that limit or closely monitor off-label use and thereby allow approval of drugs for narrowly indicated populations. © 2013 Springer Science+Business Media New York.

引用

页码：128 / 133

页数：5

共 24 条

[1]

Zuckerman D.M., FDA Advisory committees: Does approval mean safety?, (2006)

[2]

Aronne L.J., Nelinson D.S., Lillo J.L., Obesity as a disease state: a new paradigm for diagnosis and treatment, Clin Cornerstone, 9, 4, pp. 9-25, (2009)

[3]

Sumithran P., Et al., Long-term persistence of hormonal adaptations to weight loss, N Engl J Med, 365, pp. 1597-1604, (2011)

[4]

Thaler J.P., Et al., Obesity is associated with hypothalamic injury in rodents and humans, J Clin Invest, 122, 1, pp. 153-162, (2012)

[5]

Khaodhiar L., McCowen K.C., Blackburn G.L., Obesity and its comorbid conditions, Clin Cornerstone, 2, 3, pp. 17-31, (1999)

[6]

Guh D.P., Zhang W., Bansback N., Amarsi Z., Birmingham C.L., Anis A.H., The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis, BMC Publ Health, 9, (2009)

[7]

Bray G.A., Medical consequences of obesity, J Clin Endocrinol Metab, 89, 6, pp. 2583-2589, (2004)

[8]

Thompson D., Edelsberg J., Colditz G.A., Bird A.P., Oster G., LIfetime health and economic consequences of obesity, Arch Inter Med, 159, 18, pp. 2177-2183, (1999)

[9]

Fontaine K.R., Redden D.T., Wang C., Westfall A.O., Allison D.B., Years of life lost due to obesity. (2

[10]

approximately 23 to 25 for whites and 23 to 30 for blacks. For any given degree of overweight, younger adults generally had greater YLL than did older adults. The maximum YLL for white men aged 20 to 30 years with a severe level), Jama, 289, pp. 187-193, (2003)

← 1 2 3 →